ABL Diagnostics Shares Bounce Back After New Contract Through 2031
The stock of the molecular diagnostics company is regaining ground in this Friday's session, supported by the announcement of a new multi-year commercial agreement. However, the rebound remains modest in light of a still deteriorated stock market performance over recent months.
A Multi-Year Contract Through 2031 Boosts the Session
ABL Diagnostics' stock is up 2.33% at €2.64 in early afternoon trading, in a well-oriented Parisian market (the CAC 40 is up 1.79% and the SBF 120 1.75%). The stock is benefiting from the announcement, this Friday, of the signing of a multi-year contract with a European pharmaceutical laboratory specializing in neurodegenerative diseases. The agreement, managed by sister company CDL Pharma, runs until 2031 and could be worth up to €2.7 million. This announcement is part of an active period for the group, which also submitted a takeover bid for Texcell on June 9, as part of its external growth strategy in molecular diagnostics.
A Rebound That Only Marginally Corrects a Deteriorated Stock Market Performance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's movement does not change the underlying trend: the stock is still down nearly 9% for the week and has lost more than 17% over three months, with a decline of 51% over a year. The price continues to trade significantly below its three moving averages, with a gap of nearly 18% below the MM20 (€3.21) and nearly 25% below the MM200 (€3.51), reflecting an ongoing bearish dynamic at this stage. The RSI at 40 remains in the neutral zone, with no marked exhaustion of selling pressure; support is at €2.22 and the stock remains well above this level. Investors will monitor the group's ability to realize the 76.5% growth guidance for 2026 communicated at the beginning of June.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 12,3 millions d'euros
Management commentary: On June 1, 2026, ABL Diagnostics published a roadmap targeting annual revenue of €12.265 million in 2026, compared to €6.950 million in 2025, i.e. a targeted annual growth of 76.5%.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
